AQST Aquestive Therapeutics Inc
Company Analysis
Latest News
🟢 Aquestive Therapeutics is trading 6% up in pre-market
Aquestive Therapeutics is trading at $3.88, up +6.01% in pre-market; no clear overnight catalyst was identified. - On November 5, the company announced it...
🔴 Aquestive Therapeutics is trading 5% down today amid broad market and biotech pressure
Aquestive Therapeutics is trading at $3.60, down 5.13%, amid broad risk-off pressure across biotech and markets. - XBI is down 5.19% alongside steep declines...
🟢 Aquestive Therapeutics is trading 17.89% up in pre-market — no clear catalyst identified
Aquestive Therapeutics is trading 17.89% higher at $4.48 in pre-market, with no new company-specific announcement found explaining the November 5 move. - The...
Aquestive's Revenue Craters 41% on Suboxone Timing — But Can One FDA Decision in March Rewrite the Whole Story?
Shares of Aquestive Therapeutics tumbled 7.2% to $3.60 after the small-cap drugmaker posted a third-quarter earnings miss that laid bare the fragility of its...
🔴 Aquestive Therapeutics is trading 7.2% down in pre-market after third-quarter revenue and EPS misses
Aquestive Therapeutics is trading 7.2% lower at $3.60 in pre-market after third-quarter revenue and EPS misses. - Revenue was $7.6 million, down 41% year over...
Aquestive Therapeutics missed third quarter 2026 revenue and EPS estimates while securing an Anaphylm PDUFA date
Aquestive Therapeutics reported a significant revenue decline in the third quarter of 2026, largely attributed to the timing of manufacturing orders for...
🔴 Aquestive Therapeutics is trading 5% down with no confirmed catalyst
Aquestive Therapeutics is trading 5.01% lower at $3.69, with no confirmed cause identified for the November 2 decline. - Q3 results are scheduled for November...
Aquestive Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 03, 2026
Aquestive Therapeutics is expected to report Q3 2026 revenue of $15.42 million and a consensus EPS loss of $0.10, with the stock trading at $5.24 against a...
🔴 Aquestive Therapeutics is trading 5.4% down with no clear company-specific catalyst
Aquestive Therapeutics is trading at $4.00, down 5.44%, with no clear company-specific announcement explaining the October 29 decline. - The latest company...
🟢 Aquestive Therapeutics is trading 6.4% up in pre-market
Aquestive Therapeutics is trading at $4.50, up 6.4%, in pre-market; the catalyst remains unclear. - Shares are up from the October 28 close of $4.23. - No...
🔴 Aquestive Therapeutics is trading 9.1% down in pre-market with no company-specific explanation identified
Aquestive Therapeutics is trading 9.1% lower at $3.71 in pre-market on October 22, with no company-specific announcement identified to explain the decline;...
🟢 Aquestive Therapeutics is trading 5% up today with biotech shares higher
Aquestive Therapeutics is trading at $4.04, up 5.35%, with biotech-sector strength providing supportive context; the cause of today’s move is unconfirmed. - No...
Aquestive Gets a Second Shot at an Allergy Breakthrough — But Can a $500 Million Company Fund the Launch It Needs?
Shares of Aquestive Therapeutics surged +11.1% to $4.20 after the FDA accepted the company's resubmitted application for its under-the-tongue epinephrine film...
🟢 Aquestive Therapeutics is trading 11.11% up in pre-market after FDA accepts Anaphylm NDA resubmission as complete
Aquestive Therapeutics is trading at $4.20 (+11.11%) in pre-market after the FDA accepted the Anaphylm NDA resubmission as complete. - The company announced...
Aquestive Gains FDA Review for Anaphylm, the First Oral Allergy Film
Aquestive Therapeutics announced the FDA accepted its resubmitted New Drug Application for Anaphylm. The agency classified the sublingual film for severe...
🔴 Aquestive Therapeutics is trading 5.54% down with no clear company-specific catalyst
Aquestive Therapeutics is trading 5.54% lower at $3.83, with no clear company-specific news explaining the decline. - The biotech ETF XBI is down 2.06%, while...
🔴 Aquestive Therapeutics is trading 10.1% down with no clear catalyst identified
Aquestive Therapeutics is trading 10.1% down now at $4.14 on October 15, 2026, with no clear company-specific catalyst identified for the decline. - The...
🔴 Aquestive Therapeutics is trading 6.2% down; reason remains unclear
Aquestive Therapeutics is trading at $4.33, 6.2% down on October 15, 2026; available reporting does not identify a cause for the intraday decline. - The...
Aquestive Announces FDA Acceptance of Anaphylm™ NDA and Sets March 2027 PDUFA Date
Aquestive Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for Anaphylm™...
Aquestive Licenses U.S. Rights for LIBERVANT to Eton Pharma in $57.5M Deal
Aquestive Therapeutics, Inc. (AQST) has entered into an exclusive license agreement with Eton Pharmaceuticals, Inc. (Eton) for the U.S. commercialization of...